Overexpression of tumstatin in genetically modified megakaryocytes changes the proangiogenic effect of platelets

Transfusion

Volumn 54, Issue 8, 2014, Pages 2106-2117

  Li, Juan ^a   Luo, Jing ^a   Luo, Yi Qin ^a   Zhou, Ming ^a   Zhao, Liang ^a   Yao, Li Juan ^a   Dong, Hang ^a   Yang, Rui Ning ^b  

^a ANHUI PROVINCIAL HOSPITAL   (China)

^b The 81 Hospital of Peoples Liberation Army   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; TUMSTATIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL STRUCTURE; CYTOMEGALOVIRUS; GENE LOCATION; GENE OVEREXPRESSION; GENE TRANSFER; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MEGAKARYOCYTE; THROMBOCYTE; UMBILICAL VEIN ENDOTHELIAL CELL;

AUTOANTIGENS; BLOOD PLATELETS; CAPILLARIES; COLLAGEN TYPE IV; CYTOPLASMIC GRANULES; GENES, REPORTER; GENETIC VECTORS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LENTIVIRUS; MEGAKARYOCYTES; NEOVASCULARIZATION, PHYSIOLOGIC; PLATELET ACTIVATION; PLATELET AGGREGATION; RECOMBINANT FUSION PROTEINS; THROMBIN; THROMBOPOIESIS; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 84906217464     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12617     Document Type: Article

References (37)

1. Elting LS, Rubenstein EB, Martin CG, et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 2001; 19: 1137-1146.
2. Zeuner A, Signore M, Martinetti D, et al. Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor. Cancer Res 2007; 67: 4767-4773.
3. Chen TW, Hwang SM, Chu IM, et al. Characterization and transplantation of induced megakaryocytes from hematopoietic stem cells for rapid platelet recovery by a two-step serum-free procedure. Exp Hematol 2009; 37: 1330-1339.et al.
4. Scheding S, Bergmannn M, Rathke G, et al. Additional transplantation of ex vivo generated megakaryocytic cells after highdose chemotherapy. Haematologica 2004; 89: 630-631.
5. Xi J, Zhu H, Liu D, et al. Infusion of megakaryocytic progenitor products generated from cord blood hematopoietic stem/progenitor cells: results of the phase 1 study. Plos ONE 2013; 8: e54941.
6. Apelseth TO, Hervig T, Wentzel-Larsen T, et al. A prospective observational study of the effect of platelet transfusions on levels of platelet-derived cytokines, chemokines and interleukins in acute leukaemia patients with severe chemotherapy-induced cytopenia. Eur Cytokine Netw 2011; 22: 52-62.
7. Indraccolo S, Favaro E, Amadori A,. Dormant tumors awaken by a short-term angiogenic burst: the spike hypothesis. Cell Cycle 2006; 5: 1751-1755.
8. Italiano JE Jr, Richardson JL, Patel-Hett S, et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008; 111: 1227-1233.
9. Pinedo HM, Verheul HM, DAmato RJ, et al. Involvement of platelets in tumour angiogenesis? Lancet 1998; 352: 1775-1777.
10. Folkman J, Browder T, Palmblad J,. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 2001; 86: 23-33.
11. Etulain J, Fondevila C, Negrotto S, et al. Platelet-mediated angiogenesis is independent of VEGF and fully inhibited by aspirin. Br J Pharmacol 2013; 170: 255-265.
12. Brill A, Elinav H, Varon D,. Differential role of platelet granular mediators in angiogenesis. Cardiovasc Res 2004; 63: 226-235.
13. Gonzalez FJ, Rueda A, Sevilla I, et al. Shift in the balance between circulating thrombospondin-1 and vascular endothelial growth factor in cancer patients: relationship to platelet alpha-granule content and primary activation. Int J Biol Markers 2004; 19: 221-228.
14. Verheul HM, Hoekman K, Lupu F, et al. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res 2000; 6: 166-171.
15. Bastida E, Ordinas A,. Platelet contribution to the formation of metastatic foci: the role of cancer cell-induced platelet activation. Haemostasis 1988; 18: 29-36.
16. Nierodzik ML, Karpatkin S,. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006; 10: 355-362.
17. Maeshima Y, Colorado PC, Torre A, et al. Distinct anti-tumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 2000; 275: 21340-21348.
18. Maeshima Y, Colorado PC, Kalluri R,. Two RGD independent αvβ3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem 2000; 275: 23745-23750.
19. Maeshima Y, Sudhakar A, Lively JC, et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002; 295: 140-143.
20. Sudhakar A, Sugimoto H, Yang C, et al. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αvβ3 and α5β1 integrins. Proc Natl Acad Sci U S A 2003; 100: 4766-4771.
21. Kuether EL, Schroeder JA, Fahs SA, et al. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity. J Thromb Haemost 2012; 10: 1570-1580.
22. Woo SY, Kie JH, Ryu KH, et al. Megakaryothrombopoiesis during ex vivo expansion of human cord blood CD34t cells using thrombopoietin. Scand J Immunol 2002; 55: 88-95.
23. Maeshima Y, Manfredi M, Reimer C, et al. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J Biol Chem 2001; 276: 15240-15248.
24. Luo YQ, Zhou M, Zhao L, et al. Decreased tumstatin-mRNA is associated with poor outcome in patients with NSCLC. IUBMB Life 2012; 64: 423-431.
25. Caudroy S, Cucherousset J, Lorenzato M, et al. Implication of tumstatin in tumor progression of human bronchopulmonary carcinomas. Hum Pathol 2004; 35: 1218-1222.
26. Villeneuve J, Block A, Le Bousse-Kerdilès MC, et al. Tissue inhibitors of matrix metalloproteinases in platelets and megakaryocytes: a novel organization for these secreted proteins. Exp Hematol 2009; 37: 849-856.
27. Jurasz P, Sawicki G, Duszyk M, et al. Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide. Cancer Res 2001; 61: 376-382.
28. Jurasz P, Stewart MW, Radomski A, et al. Role of von Willebrand factor in tumour cell-induced platelet aggregation: differential regulation by NO and prostacyclin. Br J Pharmacol 2001; 134: 1104-1112.
29. Radomski MW, Jenkins DC, Holes L, et al. Human colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability to aggregate platelets. Cancer Res 1991; 51: 6073-6078.
30. Gasic GJ, Gasic TB, Stewart CC,. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A 1968; 48: 1172-1177.
31. Honn KV, Tang DG, Chen YQ,. Platelets and cancer metastasis: more than an epiphenomenon. Semin Thromb Hemost 1992; 18: 392-415.
32. Shi Q, Montgomery RR,. Platelets as delivery systems for disease treatments. Adv Drug Deliv Rev 2010; 62: 1196-1203.
33. Browder T, Folkman J, Pirie-Shepherd S,. The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000; 275: 1521-1524.
34. Wojtukiewicz MZ, Sierko E, Klement P, et al. The hemostatic system and angiogenesis in malignancy. Neoplasia 2001; 3: 371-384.
35. Verheul HM, Hoekman K, Luykx-de Bakker S, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997; 3: 2187-2190.
36. Verheul HM, Jorna AS, Hoekman K, et al. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 2000; 96: 4216-4221.
37. Pipili-Synetos E, Papadimitriou E, Maragoudakis ME,. Evidence that platelets promote tube formation by endothelial cells on matrigel. Br J Pharmacol 1998; 125: 1252-1257.